InflaRx (IFRX) Leerink Global Healthcare Conference 2026 summary

Strategic focus and restructuring

• Underwent restructuring after COVID-19 ARDS commercial opportunity diminished, maintaining drug availability but shifting focus.

• Core focus for 2026 is on developing izicopan, an oral C5aR inhibitor, with best-in-class potential.

• Retained a lean, intact core team to drive development and manufacturing from early stages to approval.

• Actively exploring additional indications in the immunology and inflammation (I&I) space, including ANCA vasculitis.

Clinical development and trial insights

• Completed a phase II-A open-label trial of izicopan in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), showing strong efficacy, especially in reducing draining tunnels and pain.

• Noted rapid onset and deepening of response in HS, with up to 50% of high-dose patients free of draining tunnels after four weeks.

• Observed sustained effects post-treatment, supporting potential for once-daily dosing.

• Engaged with FDA to refine endpoints beyond HiSCR, aiming to focus on more meaningful clinical outcomes like draining tunnel reduction.

Regulatory and market strategy

• Planning a Capital Markets Day in spring to provide clarity on HS development path and regulatory discussions.

• Funded into mid-2027, with plans to initiate larger phase II-B trials and explore partnerships or collaborations for broader development.

• Actively seeking strategic collaborations to expand izicopan’s potential in multiple indications.